Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Heron Therapeutics Inc (HRTX)
:HRTX
RESEARCH TOOLSreports
Holding HRTX?
Track your performance easily
HRTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.04 - $3.93
Previous CloseN/A
Volume327.52K
Average Volume (3M)4.29M
Market Cap
$238.79M
Enterprise Value$411.49M
Total Cash (Recent Filing)$51.14M
Total Debt (Recent Filing)$50.00M
Price to Earnings (P/E)―
Beta1.74
Next Earnings
Feb 20, 2025EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding152,094,910
10 Day Avg. Volume1,407,298
30 Day Avg. Volume4,292,062
Standard Deviation0.27
R-Squared0.10
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.73
Price to Cash Flow (P/CF)17.70
P/FCF Ratio20.30
Enterprise Value/Market Cap1.72
Enterprise Value/Revenue2.99
Enterprise Value/Gross Profit6.64
Enterprise Value/Ebitda-20.32
Forecast
1Y Price Target
$6.50Price Target Upside298.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Heron Therapeutics News
PremiumCompany Announcements
Heron Therapeutics Relocates Headquarters to North Carolina
PremiumMarket News
3 Penny Stocks to Watch Now, 12/5/24
Bulls Say, Bears Say
Bulls Say
Legal VictoryThe U.S. District Court for the District of Delaware found that Cinvanti patents were valid and infringed upon by Fresenius, eliminating the threat of a potential near-term generic launch.
Product EnhancementFDA approved HRTX's application for a new product presentation of Zynrelef that includes a vial access needle, simplifying and significantly reducing the product's withdrawal time from the vial.
Sales And Financial PerformanceHRTX is confident in a significant bounce-back with 4Q sales of $37MM-$43MM and positive adjusted EBITDA, driven by volume trends and new account wins.
Bears Say
EarningsHRTX reported 3Q24 top-line of $32.8MM, a significant miss vs. the Street's $36.8MM.
Product PerformanceThe main disappointment was the CINV franchise, especially Cinvanti, which ticked down due to what appears to be quarterly fluctuations.
Profitability ConcernsBased on HRTX weakness following 2Q24 earnings (and slight miss on top-line), investor focus is on quarterly numbers and progress towards profitability.
---
Ownership Overview
5.20% Insiders
8.78% Mutual Funds
1.68% Other Institutional Investors
75.16% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HRTX FAQ
What was Heron Therapeutics Inc’s price range in the past 12 months?
Heron Therapeutics Inc lowest stock price was $1.04 and its highest was $3.93 in the past 12 months.
What is Heron Therapeutics Inc’s market cap?
Heron Therapeutics Inc’s market cap is $238.79M.
When is Heron Therapeutics Inc’s upcoming earnings report date?
Heron Therapeutics Inc’s upcoming earnings report date is Feb 20, 2025 which is in 30 days.
How were Heron Therapeutics Inc’s earnings last quarter?
Heron Therapeutics Inc released its earnings results on Nov 12, 2024. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.038 by $0.008.
Is Heron Therapeutics Inc overvalued?
According to Wall Street analysts Heron Therapeutics Inc’s price is currently Undervalued.
Does Heron Therapeutics Inc pay dividends?
Heron Therapeutics Inc does not currently pay dividends.
What is Heron Therapeutics Inc’s EPS estimate?
Heron Therapeutics Inc’s EPS estimate is -0.03.
How many shares outstanding does Heron Therapeutics Inc have?
Heron Therapeutics Inc has 152,094,910 shares outstanding.
What happened to Heron Therapeutics Inc’s price movement after its last earnings report?
Heron Therapeutics Inc reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.038. Following the earnings report the stock price went down -30.435%.
Which hedge fund is a major shareholder of Heron Therapeutics Inc?
Among the largest hedge funds holding Heron Therapeutics Inc’s share is EntryPoint Capital, LLC. It holds Heron Therapeutics Inc’s shares valued at 30K.
---
Heron Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.50 (298.77% Upside)
$6.50 (298.77% Upside)
Blogger Sentiment
Bearish
HRTX Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 221.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 3.4%
Last 30 Days ▲ 3.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.90%
12-Months-Change
Fundamentals
Return on Equity
69.91%
Trailing 12-Months
Asset Growth
-3.67%
Trailing 12-Months
Company Description
Heron Therapeutics Inc
Heron Therapeutics, Inc. is a biotechnology company, which develops pharmaceutical products for patients suffering from cancer. The company develops products by using its proprietary Biochronomer polymer based drug delivery technology. Its products include SUSTOL, Pipeline, Cinvanti and HTX-011. The company has additional clinical and preclinical-stage programs in the area of pain management, all of which utilize its bio erodible, injectable and implantable delivery systems. Heron Therapeutics was founded in February 1983 and is headquartered in Redwood City, CA.
---
HRTX Company Deck
---
HRTX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook with significant achievements, including revenue growth, cost management, and strategic advancements like the VAN approval and NOPAIN Act inclusion. However, challenges remain with specific product revenue declines and financial write-offs.Read More>---
HRTX Stock 12 Month Forecast
Average Price Target
$6.50
▲(298.77% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Axsome Therapeutics
―
BioCryst
―
Amicus
―
Karyopharm Therapeutics
―
Protagonist Therapeutics
―
Best Analysts Covering HRTX
1 Year
1 Year Success Rate
5/32 ratings generated profit
1 Year Average Return
-31.14%
reiterated a buy rating 2 months ago
Copying Serge Belanger's trades and holding each position for 1 Year would result in 15.63% of your transactions generating a profit, with an average return of -31.14% per trade.
---